Realistically, radiosensitivity of the tested cell lines must be influenced not only by EGFR but also by other genetic aberrations; therefore, clinical tumor radioresponsiveness will be more accurately predicted by genetic profiles comprising multiple genes, which warrants further investigation. The gene discussed is EGFR; the disease is neoplasm.